Department of Health Policy and Management, Erasmus University, Rotterdam, the Netherlands.
Pharmacoeconomics. 2011 Jul;29(7):601-19. doi: 10.2165/11539970-000000000-00000.
When guidelines for health economic evaluations prescribe that a societal perspective should be adopted, productivity costs should be included. However, previous research suggests that, in practice, productivity costs are often neglected. This may considerably bias the results of cost-effectiveness studies, particularly those regarding treatments targeted at diseases with a high incidence rate in the working population, such as depressive disorders.
This study aimed to, first, investigate whether economic evaluations of treatments for depressive disorders include productivity costs and, if so, how. Second, to investigate how the inclusion or exclusion of productivity costs affects incremental costs.
A systematic literature review was performed. Included articles were reviewed to determine (i) whether productivity costs had been included and (ii) whether the studies adhered to national health economic guidelines about the inclusion or exclusion of these costs. For those studies that did include productivity costs, we calculated what proportion of total costs were productivity costs. Subsequently, the incremental costs, excluding productivity costs, were calculated and compared with the incremental costs presented in the original article, to analyse the impact of productivity costs on final results. Regression analyses were used to investigate the relationship between the level of productivity costs and the type of depressive disorder, the type of treatment and study characteristics such as time horizon used and productivity cost valuation method.
A total of 81 unique economic evaluations of treatments for adults with depressive disorders were identified, 24 of which included productivity costs in the numerator and one in the denominator. Approximately 69% of the economic evaluations ignored productivity costs. Two-thirds of the studies complied with national guidelines regarding the inclusion of productivity costs. For the studies that included productivity costs, these costs reflected an average of 60% of total costs per treatment arm. The inclusion or exclusion of productivity costs substantially affected incremental costs in a number of studies. Regression analyses showed that the level of productivity costs was significantly associated with study characteristics such as average age, the methods of data collection regarding work time lost, the values attached to lost work time, the type of depressive disorder, the type of treatment provided and the level of direct costs.
Studies that do not include productivity costs may, in many cases, poorly reflect full societal costs (or savings) of an intervention. Furthermore, when comparing total costs reported in studies that include productivity costs, it should be noted that study characteristics such as the methods used to assess productivity costs may affect their level.
当健康经济评估指南规定应采用社会视角时,应包括生产力成本。然而,先前的研究表明,在实践中,生产力成本经常被忽视。这可能会极大地影响成本效益研究的结果,特别是那些针对工作人群中发病率较高的疾病(如抑郁症)的治疗方法。
本研究旨在首先调查治疗抑郁症的经济评估是否包括生产力成本,如果包括,如何包括。其次,研究包括或排除生产力成本如何影响增量成本。
进行了系统的文献综述。对纳入的文章进行了审查,以确定(i)是否包括了生产力成本,以及(ii)研究是否遵守了关于包括或排除这些成本的国家健康经济指南。对于那些确实包括生产力成本的研究,我们计算了总成本中生产力成本的比例。随后,计算了不包括生产力成本的增量成本,并与原始文章中报告的增量成本进行了比较,以分析生产力成本对最终结果的影响。回归分析用于研究生产力成本水平与抑郁障碍类型、治疗类型以及使用的时间范围和生产力成本估值方法等研究特征之间的关系。
共确定了 81 项针对成年人抑郁症治疗的独特经济评估,其中 24 项在分子中包括了生产力成本,1 项在分母中包括了生产力成本。大约 69%的经济评估忽略了生产力成本。三分之二的研究符合关于纳入生产力成本的国家指南。对于那些包括生产力成本的研究,这些成本反映了每个治疗组总成本的平均 60%。在许多研究中,包括或排除生产力成本会极大地影响增量成本。回归分析表明,生产力成本水平与研究特征显著相关,例如平均年龄、关于失去工作时间的数据收集方法、失去工作时间的价值、抑郁障碍类型、提供的治疗类型以及直接成本水平。
在许多情况下,不包括生产力成本的研究可能无法充分反映干预措施的全部社会成本(或节省)。此外,在比较包括生产力成本的研究中报告的总成本时,应注意用于评估生产力成本的方法等研究特征可能会影响其水平。